Project Grant R35GM164323
- The National Institute of General Medical Sciences awarded The Mount Desert Island Biological Laboratory $422,500 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate molecular mechanisms of limb and tail regeneration in axolotls as a foundation for developing strategies for scarless tissue regeneration in humans. The research examines why axolotls regenerate limbs and tails without scarring through blastema formation, whereas mammals form...
- The National Institute of Child Health and Human Development awarded The Marine Biological Laboratory $431,112 on September 1, 2026, under the Child Health and Human Development Extramular Research program (CFDA 93.865) to investigate the role of neuropeptides in appendage regeneration. The research seeks to understand why salamanders and axolotls regenerate lost limbs, jaws, tails, and other tissues while humans retain only limited regenerative capacity. The work addresses therapeutic...
- The National Institute of General Medical Sciences awarded Louisiana State University $375,000 on September 4, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to fund a five-year comparative study identifying shared molecular and cellular mechanisms of limb and fin regeneration across regenerative and non-regenerative vertebrate species. The research employs a multiscale comparative approach using the axolotl (Mexican salamander), Senegal bichir, African lungfish,...
- The National Institute of General Medical Sciences, part of the National Institutes of Health, awarded the University of California, Davis $393,008 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on the regulation of cell fate specification during the regeneration of complex sensory organs. The funded research uses the freshwater apple snail (Pomacea canaliculata) as a model organism to uncover molecular mechanisms driving...
- The National Institute of General Medical Sciences awarded the University of Washington $397,158 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct research on the biosynthesis, discovery, and biocatalytic production of halogenated nucleosides and nucleoside-sulfamates. The research will investigate biosynthesis pathways of natural product nucleoside analogs containing rare functional groups, with emphasis on identifying key enzymes involved in...
- The National Institute of General Medical Sciences awarded Vanderbilt University $435,875 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on epigenetic control of tissue regeneration across species and life stages. The award funds investigation into how gene activity is regulated to enable tissue regeneration in organisms such as planarians, teleost fish, and salamanders that retain regenerative capacity throughout their lives,...
- The National Institute of General Medical Sciences awarded the University of Denver $406,667 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate post-transcriptional regulation of tissue regeneration by ribonucleoprotein granules, specifically P-bodies. The project will determine the composition of regenerative P-bodies using in vivo proximity labeling and super-resolution microscopy, and will bioengineer artificial P-bodies to test their...
- The National Institute of General Medical Sciences awarded the Seattle Institute For Biomedical And Clinical Research $374,550 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate molecular regulation of endothelial glycocalyx-mediated transcytosis. The work characterizes molecular components that regulate transendothelial transport of chemokines and viral proteins across endothelial cell barriers, with emphasis on tissue-specific and...
- The National Institute of General Medical Sciences awarded the University of Washington $380,371 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop computational methods that infer cellular history from single-cell sequencing data, enabling analysis of disease progression in tissues that cannot be sampled longitudinally, such as the brain in Alzheimer's disease or the heart in cardiomyopathy. The research deploys three integrated approaches:...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services, awarded $153,560 to the University of California, Santa Barbara on November 21, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, Assistance Listing). The recipient will conduct physiological, molecular, and bioinformatic experiments to determine the role of circadian rhythms in modulating wound healing and whole-body regeneration, with focus on identifying the...
The National Institute of General Medical Sciences awarded the University of Washington $287,219 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate metabolic reprogramming in vertebrate appendage regeneration. The research examines how animals mobilize biomolecules—nucleotides, proteins, and lipids—to regrow lost appendages, using the frog Xenopus tropicalis as a model organism. The principal investigator's central hypothesis is that regenerating tissues remodel metabolism by redirecting nutrients away from oxidative metabolism toward biosynthesis. The research will answer two questions: what metabolic features facilitate or constrain regenerative outcomes across developmental stages and tissue structures, and how are metabolic responses to injury regulated intracellularly and extracellularly. The work will contrast metabolic responses to injury in regenerative versus non-regenerative structures, test the contributions of intracellular purine biosynthesis regulation to regeneration, and examine endocrine modulation of metabolism by thyroid hormone. Performance occurs in Seattle, Washington. The period of performance runs from August 1, 2026, through March 31, 2031. This is a Project Grant, a form of assistance funding supporting investigator-initiated research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $287.2k | 7/21/26 |